OPK vs. INVA, MNKD, LGND, PCRX, IRWD, LXRX, ADCT, AVIR, XOMA, and VNDA
Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Innoviva (INVA), MannKind (MNKD), Ligand Pharmaceuticals (LGND), Pacira BioSciences (PCRX), Ironwood Pharmaceuticals (IRWD), Lexicon Pharmaceuticals (LXRX), ADC Therapeutics (ADCT), Atea Pharmaceuticals (AVIR), XOMA (XOMA), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
Innoviva (NASDAQ:INVA) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.
99.1% of Innoviva shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 1.4% of Innoviva shares are owned by company insiders. Comparatively, 47.3% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
OPKO Health has a consensus target price of $3.73, indicating a potential upside of 200.40%. Given Innoviva's higher possible upside, analysts plainly believe OPKO Health is more favorable than Innoviva.
Innoviva has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.
In the previous week, OPKO Health had 1 more articles in the media than Innoviva. MarketBeat recorded 4 mentions for OPKO Health and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.31 beat OPKO Health's score of 1.21 indicating that OPKO Health is being referred to more favorably in the news media.
OPKO Health received 202 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 65.83% of users gave OPKO Health an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Innoviva has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Innoviva has a net margin of 57.89% compared to Innoviva's net margin of -21.76%. OPKO Health's return on equity of 30.37% beat Innoviva's return on equity.
Summary
OPKO Health beats Innoviva on 9 of the 17 factors compared between the two stocks.
Get OPKO Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OPKO Health Competitors List
Related Companies and Tools
